What the FDA labels say about taking them together
Alteplase and defibrotide
Defibrotide's FDA label of July 1, 2025 names alteplase in its drug interactions section; the alteplase label PlainMeds reads does not name defibrotide.
Check it at the source: the alteplase FDA label on DailyMed (effective January 20, 2026, Genentech, Inc.); the defibrotide FDA label on DailyMed (effective July 1, 2025, Jazz Pharmaceuticals, Inc.).
What does the alteplase label say about defibrotide?
Alteplase's label (effective January 20, 2026) does not name defibrotide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Activase), Genentech, Inc., effective January 20, 2026 (SPL set c669f77c-fa48-478b-a14b-80b20a0139c2), via openFDA; the full label on DailyMed
What does the defibrotide label say about alteplase?
Defibrotide label, drug interactionsDRUG INTERACTIONS Antithrombotic Agents DEFITELIO may enhance the pharmacodynamic activity of antithrombotic/fibrinolytic drugs such as heparin or alteplase.
Source: FDA drug label (DEFITELIO), Jazz Pharmaceuticals, Inc., effective July 1, 2025 (SPL set 2c3db989-d7ad-41ed-9ebf-698dcf6c24ec), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Alteplase | Defibrotide | |
|---|---|---|
| Labeled for | Heart attack and coronary artery disease, Blood clots (DVT and PE) | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $186.38 per vial 2 mg vial | n/a |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once